Literature DB >> 6766359

In vitro cytotoxicity of the methylmelamines.

C J Rutty, G Abel.   

Abstract

Hexamethylmelamine (HMM) and a number of its derivatives are toxic to PC6 plasmacytoma cells in vitro. However, there is no correlation between in vitro cytotoxicity and activity against this tumour in vivo. N-Methylolmelamines are significantly more toxic than HMM itself. These compounds break down to release formaldehyde which is itself a highly cytotoxic agent. Pentamethylmonomethylolmelamine rapidly inhibits the growth of PC6 cells in culture, whereas HMM and pentamethylmelamine (PMM) require prolonged contact with the cells in order to exert a cytotoxic effect. HMM and its metabolites are also toxic to a number of other cell lines. The toxicity of the N-methylols to cultured L1210 leukaemia and Walker 256 ascites cells appears to be due entirely to formaldehyde release, whereas in PC6 cells the methylols appear to be acting more selectively.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6766359     DOI: 10.1016/0009-2797(80)90036-8

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  11 in total

1.  Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.

Authors:  C J Rutty; I R Judson; G Abel; P M Goddard; D R Newell; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.

Authors:  C J Rutty; D R Newell; J R Muindi; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 3.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 4.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Comparative studies of DNA cross-linking reactions following methylene dimethanesulphonate and its hydrolytic product, formaldehyde.

Authors:  P M O'Connor; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.

Authors:  K J Miller; R M McGovern; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 7.  Clinical pharmacokinetics of altretamine.

Authors:  G Damia; M D'Incalci
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

8.  Phase II trial of trimelamol in refractory ovarian cancer.

Authors:  I R Judson; A H Calvert; M E Gore; K Balmanno; L A Gumbrell; T Perren; E Wiltshaw
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

9.  Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.

Authors:  J R Muindi; D R Newell; I E Smith; K R Harrap
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

10.  Clinical correlates of in vitro drug sensitivities of ovarian cancer cells.

Authors:  L Morasca; E Erba; M Vaghi; C Ghelardoni; C Mangioni; C Sessa; F Landoni; S Garattini
Journal:  Br J Cancer       Date:  1983-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.